secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOXYTRAN, INC (BIXT)
CIK:        0001445815
Form:       8-K
Filed at:   2026-02-17T23:59:59+00:00
Accession:  0001493152-26-006891
Event type: other_material
Sentiment:  positive
Materiality: 0.50
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bioxytran signs distribution deal with Khoury Medical for A-SUQAR supplement
----------------------------------------------------------------------------

- Agreement with Khoury Medical to commercialize A-SUQAR, a chewable blood sugar supplement using Bioxytran's PHGG formulation.
- CEO David Platt says deal marks transition from development-stage to recurring commercial revenue while preserving IP ownership.
- Volume-based marketplace exclusivity possible if defined purchase thresholds are met, per agreement terms.
- Initial commercial shipments expected after completion of standard launch preparations; manufacturing by Bioxytran's OEM.
- Bioxytran retains full IP; deal applies only to non-pharmaceutical dietary products, preserving pharma/antiviral programs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1445815/000149315226006891/0001493152-26-006891-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1445815/000149315226006891/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-006891

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer